Immunome, Inc. (IMNM)
| Market Cap | 1.81B |
| Revenue (ttm) | 9.68M |
| Net Income (ttm) | -222.74M |
| Shares Out | 91.71M |
| EPS (ttm) | -2.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,768,114 |
| Open | 21.60 |
| Previous Close | 23.48 |
| Day's Range | 19.77 - 21.93 |
| 52-Week Range | 5.15 - 25.30 |
| Beta | 2.18 |
| Analysts | Strong Buy |
| Price Target | 31.44 (+58.95%) |
| Earnings Date | Nov 6, 2025 |
About IMNM
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-13... [Read more]
Financial Performance
In 2024, Immunome's revenue was $9.04 million, a decrease of -35.50% compared to the previous year's $14.02 million. Losses were -$292.96 million, 174.3% more than in 2023.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for IMNM stock is "Strong Buy." The 12-month stock price target is $31.44, which is an increase of 58.95% from the latest price.
News
Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat
Immunome (IMNM) delivered statistically significant phase 3 RINGSIDE results for varegacestat in progressive desmoid tumors, achieving an 84% risk reduction in progression or death compared to placebo...
Immunome Announces Pricing of Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced t...
Immunome Announces Proposed Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced i...
Immunome's experimental drug meets main goal in late-stage study
Immunome said on Monday its experimental drug met main goal in a late-stage study for patients with a rare type of tumor.
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive top...
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company wi...
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced toda...
Immunome to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members o...
Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu...
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome ...
Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical...
Infinimmune Announces Research Collaboration with Immunome
ALAMEDA, Calif.--(BUSINESS WIRE)-- #antibodies--Infinimmune Announces Research Collaboration with Immunome.
Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome ...
Immunome: SpringWorks Buyout Informs The Potential Upside Here
Immunome's lead asset, varegacestat, shows promising efficacy in desmoid tumors, with phase 3 topline data expected by the end of 2025. IMNM holds Orphan Drug designations in the US and Europe, potent...
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu...
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu...
Immunome: Transformed Pipeline Offers Multiple Catalysts
Immunome's unique human immune memory-based discovery engine and strategic pipeline expansion in oncology present a compelling investment opportunity, especially post-merger with Morphimmune. The comp...
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome ...
Immunome Reports Full Year 2024 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu...
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that the first...
Immunome to Present at Upcoming March Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will p...
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced t...
Immunome Can Take The Fight To Competitors With Varegacestat
Immunome Can Take The Fight To Competitors With Varegacestat
Immunome Announces Pricing of Upsized Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced t...
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg...